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Antimicrobial resistance represents a significant global health threat. However, a commercial model that
does not offer a return on investment resulting in a lack of investment in antibiotic R&D, means that the
current pipeline of antibiotics lacks sufficient innovation to meet this challenge. Those responsible for
defining, promoting and monitoring the rationale use of antibiotics (the antimicrobial stewardship pro-
gramme) are key to addressing current shortcomings. In this personal perspective, we discuss the future
role stewardship can play in stimulating innovation, a need to move away from a pharmacy budget dom-
inated view of antibiotic use, and the impact of the ever-increasing sophistication and interdisciplinary
nature of antimicrobial control programs. Changes are needed to optimize clinical outcomes for patients.
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Antibiotics represent one of the most important components of the modern medical armamentarium. However,
the inevitable development of antimicrobial resistance has resulted in an alarming prevalence of multidrug-resistant
organisms. Despite the clear medical need for new agents, the clinical development pipeline for antibiotics is sparse.
Except for bedaquiline for MDR-TB, no antibiotics with a novel mechanism of action have been approved for
human use since daptomycin in 2002. While valuable agents have been approved since, which address specific
resistance mechanisms or provide alternative pharmacokinetics such as dalbavancin and the other lipoglycopeptides,
these drugs are analogs of known classes that offer incremental benefit over other class members (Table 1). They
are typically broad-spectrum agents, developed for more than one indication and often for labeled indications with
low unmet medical need; characteristics that may promote resistance. Continued development of next generation
drugs is only a stop-gap approach, since resistance mechanisms to these classes already exist and bacteria are only
one short step away from adapting to the latest analog [1]. For example, resistance to ceftazidime/avibactam and
ceftolozane/tazobactam emerged soon after approval, and indeed before frequent prescribing of these agents had
occurred [2,3]. In addition, newer generations of antibiotics have not always produced beneficial drugs, as shown by
the relative toxicity of many later fluoroquinolones, resulting in market withdrawals.
A key contributor to the lack of novel antibiotics is that commercial returns have been meager, and the sector
is increasingly considered as unattractive to developers, resulting in a lack of investment and innovation. New
antibiotics are perceived as ‘break-glass-in-emergency’ medicines that we should all have but use only in the direst
of emergencies. To help address this, several ‘push’ mechanisms have been established to support R&D [4]. While
significantly contributing to much-needed investment, they do not address the commercial issues and various
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Table 1. Antibiotic approvals since 2002.
Drug Class Mechanism Approved indication(s) Year of first approval
Tigecycline Tetracycline 30S ribosome subunit cSSSI, cIAI, CABP† 2005
Doripenem‡ Carbapenem PBP cIAI, cUTI 2005
Ceftobiprole§ Cephalosporin PBP CAP, HAP 2008
Ceftaroline Cephalosporin PBP ASSSI, CABP 2010
Fidaxomicin Macrolide RNA polymerase CDI 2011
Bedaquiline Novel ATP synthase TB 2012
Telavancin‡ Glycopeptide Peptidoglycan crosslinking cSSSI 2013
Tedizolid Oxazolidinone 50S ribosome subunit ABSSI 2014
Dalbavancin Glycopeptide Peptidoglycan crosslinking ABSSI 2014
Oritivancin Glycopeptide Peptidoglycan crosslinking ABSSI 2014
Ceftolozane/tazobactam Cephalosporin/BLI PBP/-lactamase cIAI, cUTI 2014
Ceftazidime/avibactam Cephalosporin/BLI PBP/-lactamase HAP/VAP, cIAI, cUTI 2015
Meropenem/vaborbactam Carbapenem/BLI PBP/-lactamase cUTI, cIAI¶, HAP/VAP¶ 2017
Delafloxacin# Fluoroquinolone DNA gyrase SSSI 2017
Plazomicin# Aminoglycoside 30S ribosome subunit cUTI 2017
Eravacycline Tetracycline 30S ribosome subunit cIAI 2018
Omadacyline# Tetracycline 30S ribosome subunit SSSI, CAP 2018
Imipenem-cilastatin-relebactam# Carbapenem-BLI PBP/-lactamase cIAI, cUTI 2019
†US FDA approved indication only.
‡EMA market authorization withdrawn.
§European and Canadian approval only.
¶EMA approved indication only.
#Marketing authorization application under review with EMA CHMP.
BLI: -lactamase inhibitor; CHMP: Committee for Medicinal Products for Human Use; EMA: European Medicines Agency; PBP: Penicillin binding protein.
economic models (‘pull’ mechanisms) have been suggested, with most based on a Market Entry Reward (MER)
– a form of economic prize on approval of a new antibiotic [5]. While efforts made to propose such models are
welcome, implementation in the near future is uncertain. The MERs require significant political and societal
will and, importantly, international collaboration. How they could be implemented (e.g., at a global or national
level) and who would control these is unknown. Other solutions have been proposed such as creating nonprofit
organizations to take over the role of discovery and development of antibiotics [6]. However, as forMERs the funding
and sustainability of such organizations, along with building the required skills and resources, poses significant
challenges.
The role of antimicrobial stewardship
Given both the emergence of resistance and lack of new agents, there has been increased focus on the prudent use
of antibiotics. From the 1970s, when programs to control antibiotic use emerged through the initial proposal of the
term ‘stewardship’ [7], antimicrobial stewardship programs (ASP) have become central to treating infections. The
National Action Plan issued by the White House [8], called for ASPs to be established in all acute care hospitals by
2020 and by 2016, 64.2% of US hospitals had met the CDC core elements of stewardship [9]. In Europe, numerous
initiatives have been instigated at European wide, national and regional levels [10], with ESGAP, the ESCMID Study
Group for antimicrobial stewardship, playing a particularly active role.
The term stewardship has evolved over time [11], and today numerous definitions of stewardship exist (Box 1). All
describe a multidisciplinary approach (including pharmacists, physicians, microbiologists and infection control) to
the appropriate use of antibiotics to optimize patient outcomes by ensuring the right drug, dose and duration are
administered. As recommended by The Infectious Diseases Society of America (IDSA) [12], core to ASPs is either
a preauthorization and/or prospective audit and feedback (PAF) system. Restrictive preauthorization programs
require clinicians to secure approval from an ASP to use certain antibiotics while PAF proactively engages with
the physician once the antibiotic has been prescribed. Effective examples of preauthorization programs have been
reported [13,14]. However, they require real time authorization, which is often not available, and restriction alone
may cause issues unless implemented with a high degree of skill as reviewed by Garau [15]. In particular, delays
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Box 1. Definitions of antimicrobial stewardship.
• Infectious Diseases Society of America, SHEA, PIDS Consensus statement: “coordinated interventions designed to
improve and measure the appropriate use of (antibiotic) agents by promoting the selection of the optimal
(antibiotic) drug regimen including dosing, duration of therapy and route of administration.”
• CDC: “antimicrobial stewardship programs can optimize treatment of infections and antibiotic use – with the
goal to provide every patient with the right antibiotics, at the right time, at the right dose and for the right
duration – to reduce adverse events associated with antibiotics and improve patient outcomes.”
• NICE: “an organizational or healthcare-system-wide approach to promoting and monitoring judicious use of
antimicrobials to preserve their future effectiveness.”
• WHO: “framework to preserve antimicrobial medicines by taking measures to promote their control, appropriate
distribution as well as appropriate use.”
• Duke Center for Antimicrobial Stewardship and Infection Prevention: our mission remains driven by two goals –
to improve patient safety and enhance quality of care.
to appropriate therapy and placing undue access barriers to physician’s optimal choice of therapy may lead to
poorer clinical outcomes, including excess mortality. Examples of the impact of inappropriate therapy include a
recent systematic review and meta-analysis of outcomes in severe Gram-negative infections showing an increased
risk of mortality (adjusted OR: 3.30; 95% CI: 2.42–4.49) [16], and a retrospective cohort study of the premier
perspective database (2009–2013) of carbapenem resistance andEnterobacteriaceae infections also showing increased
mortality (12.2 vs 9.9%; p < 0.001) [17]. Restriction of an agent may result in the ‘squeeze the balloon effect’,
first coined by Burke [18]. For example, Rahal observed that a preauthorization requirement for cephalosporins
reduced the incidence of ceftazidime-resistant Klebsiella spp. by 44%, but was associated with a concomitant
increase in imipenem use and a 68.7% increase in the incidence of imipenem-resistant Pseudomonas aeruginosa [19].
Thus, restriction can lead to both desirable and undesirable consequences, and Rahal later emphasized the need to
‘squeeze the balloon’ at multiple sites [20].
PAF approaches proactively engagewith physicians to educate and informwhilemaintaining prescribing freedom.
Direct comparisons between the approaches are few, although a recent Cochrane review [21] noted preauthorization
approaches could be detrimental to communication between clinical and ASP teams and ultimately concluded
enablement approaches (e.g. PFA) consistently increased the effect of ASP interventions. This has been noted by
others [22]. A Cochrane meta-analysis also noted restrictive interventions were more effective only when the need is
urgent [23]. Tamma et al. showed, in a quasi-experimental crossover trial comparing restriction or PFA, that PFA
was more effective at reducing antibiotic usage, determined by days of therapy (DOTs), with median values of eight
and six DOT per 1000 patient-days (p = 0.03) for restrictive and PFA approaches, respectively [24].
To assess an ASP’s impact, performance measures are required covering clinical, microbiological, consumption
and financial elements [25,26]. The IDSA guidelines recommend the best measure is monitoring antibiotic use, ideally
by DOTs, with expenditure assessed on prescriptions. However, the latter only measures drug acquisition costs, and
not total care costs that represent a more meaningful economic indicator [12]. To truly meet the objectives of ASPs,
which should be to ensure that judicious antimicrobial use optimizes clinical outcomes, measures such as resistance,
mortality, readmissions, length of stay and oral switch would be more meaningful. However, the complexity of
collecting and interpreting such data often restricts ASPs to focusing on antibiotic usage and acquisition cost, despite
a measured reduction in antibiotic usage not confirming a successfully implemented ASP; it is simply a process
outcome [27,28]. Spellberg and colleagues discussed how to justify implementation of impactful ASPs in a way
that resonates with healthcare administrators, who are invariably dealing with budgets requiring implementation
of one program to be at the expense of spend in other areas [29]. To those within, and expert on, ASPs metrics
such as antibiotic usage may enable them to understand the wider benefits of stewardship and convey success
messages, but it creates a perception stewardship is primarily about reducing costs. That perception is held, not
only by those outside of the healthcare system, but potentially by some physicians whose prescribing decisions
may be unduly influenced toward economic, and away from clinical outcome, considerations. A recent survey of
1044 IDSA EIN members indicated that 87% of hospital providers considered cost reduction a major driver of
ASPs [30]. This finding is stark, given antibiotic costs are not mentioned in ASP definitions. Similarly, a survey of
ASPs in 82 acute care institutions in Florida reported the most common outcome measure by 56 facilities was
drug purchasing costs (70%); only 43, 38 and 34% of facilities assessed patient outcomes, LOS, and adverse drug
reactions, respectively. In addition, of perceived reasons for antimicrobial misuse, 84% of clinicians feared being
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sued for untreated infections [31]; further evidence of the undue pressures on prescribers promoting inappropriate
antibiotic use. A recent worldwide review of studies, including many from European countries, that assessed the
impact of quality measures in ASPs noted only 13 of 63 studies reported on patient outcomes such as mortality
and length of stay. In contrast, 21 of the 63 studies reported only on cost savings and antimicrobial usage with the
remainder reporting on resistance and/or CDI rates [32]. In 2019, The Consensus on Antimicrobial Stewardship
Evaluations study group published a comprehensive systematic review of the quality of antimicrobial stewardship
studies as part of a process to develop recommendations to improve the quality of such studies [33]. The findings
clearly showed that the design quality of stewardship evaluations was poor, had not improved during the period
under review (1950–2017) and that the majority reported on process outcomes only. For hospital studies, 46 and
72% did not report on clinical or microbiological outcomes, respectively; in other words, the outcome measures
that would most meaningfully describe an ASPs benefit to patients. While well-developed and sophisticated ASPs
have reported high quality studies and assessments [34], the results reported by the Consensus on Antimicrobial
Stewardship Evaluation study group suggest a different picture in the majority of ASPs.
As noted by many, measuring ASP performance purely on acquisition costs results in policies naturally restricting
more expensive, yet potentially superior agents driving overutilization of less effective drugs [35,36]. As discussed
by Cunha, restriction should only be for agents with high resistance potential [37], and low cost antibiotics may
have higher overall total costs when considering Clostidium difficile infection (CDI), resistance and poorer clinical
outcomes. A review by Emberger et al. described two important expert stewardship panels that were convened to
define outcome metrics and that neither recommended cost [28].
Acquisition cost metrics are likely used as they are probably the simplest to gather yet if financial considerations
are to be made they should be focused on reducing unneeded antibiotic use, on total care costs and not solely on
acquisition costs; especially as healthcare reforms are shifting toward quality of care and away from fee-for-service
models [38]. The CDC’s most recent report on antibiotic use in the US highlights, despite improvements, continued
high level use of unnecessary antibiotics with approximately 47 million antibiotic courses prescribed each year for
infections that do not require antibiotic therapy and that often the recommended agents and duration of therapy
were not selected [39]. This continued inappropriate antibiotic use not only contravenes the principles of stewardship
putting patients at risk of harm but is a significant financial and resource drain.
Perhaps this describes why that, despite stewardship aiming to ensure antibiotics are used to optimize clinical
outcomes, there are areas where this appears not to be happening. Carbapenem-resistant Enterobacteriaceae (CREs)
are among themostworrisome drug resistant pathogens [40], and effective agents against these infections have recently
been approved and others are in late stage development [41]. A Phase III study comparing meropenem/vaborbactam
with best available therapy in patients with suspected or confirmed CRE infection at a range of body sites (cUTI/AP,
HABP, VABP, cIAI and bacteraemia) was halted on the recommendation of the Data and Safety Monitoring
Board (DSMB) due to higher cure rates, and reduced mortality and nephrotoxicity in meropenem/vaborbactam
recipients [42]. Although the sample size was small, the data were encouraging; estimated improvement in cure
at TOC was 32.7% (95% CI: 4.6–60.8) associated with an estimated 17.7% (95% CI: -44.7–9.3) reduction
in day 28 mortality. Similar superiority for cure and mortality have been reported with other agents including
ceftazidime/avibactam [43,44]. Kadri et al. recently proposed a phenotypic susceptibility definition of difficult-to-
treat resistance (DTR) defined as resistance to at least one member of all β-lactam classes and fluoroquinolones; in
other words, agents considered first-line, high efficacy and low toxicity. Mortality following BSI caused by DTR
(typically treated with tigecycline, aminoglycosides or colistin) compared with non-DTR Gram-negative bacteria
was 40% higher; adjustedmortality risk 1.4 (95%CI: 1.2–1.6; p< 0.001) [45]. These data are important evidence of
the adverse patient impact of using less efficacious and potentially more toxic antibiotics. However, uptake of these
new agents into practice is unacceptably slow. A recent study across 132 US hospitals, using a clinical administration
database, showed that the median time to first use (range) of ceftazidime/avibactam and ceftolozane/tazobactam
was 463 days (48 to >1200) and 405 days (13 to >1268), respectively [46]. In another study, investigators using
IQVIA antibiotic prescription data estimated that more CRE infections in the USAwere treated with an intravenous
polymyxin than a new anti-CRE agent (ceftazidime/avibactam, meropenem/vaborbactam and plazomicin) from
February 2018 to January 2019 (Figure 1) [47]. Use of new agents did not exceed that of intravenous polymyxins
until December 2018. These data were discordant with results from a survey of US hospital-based pharmacists,
which indicated that the new agents were positioned as first-line against CRE urinary tract and nonurinary tract
infections at approximately 50 and 90% of centers, respectively. Anti-CRE drugs were estimated to treat only
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Figure 1. Estimated number of colistin, polymyxin B, ceftazidime/avibactam, meropenem/vaborbactam and plazomicin treatment
courses for carbapenem-resistant Enterobacteriaceae infections.
C-A: Ceftazidime-avibactam; COL: Colistin; CRE: Carbapenem-resistant Enterobacteriaceae; M-V: Meropenem-vaborbactam; PB: Polymyxin
B; PLZ: Plazomicin.
35% (range: 23–62%) of CRE infections in which they were expected to be first-line agents. Clearly, research on
behavioral and economic factors that impact use of the new drugs and polymyxins is needed.
If continued reliance on colistin is due to restriction of more efficacious, less toxic, but more expensive agents,
then we are failing in our responsibilities to severely ill, vulnerable patients. Colistin, a drug made available prior to
the 1962 US FDA Kefauver-Harris Drug Amendments requiring proof of safety and efficacy for FDA marketing
approval, would be unlikely to receive regulatory approval today, is not primum non nocere, and use should be
restricted beyond that of the newly available therapies
CDI is another scenario characterized by frequent prescribing of older antibiotics despite alternatives with better
patient outcomes being available. CDIs are often treated with oral vancomycin or metronidazole and in the case, of
metronidazole, we know that this option is inferior to vancomycin [48]. Oral vancomycin raises potential resistance
issues with VRE selection and our awareness of the gut microbiota as a reservoir of resistance mechanisms and
source of infection continues to increase [49]. In addition, vancomycin is associated with unacceptable rates of
recurrent CDI, induced by collateral damage to the gut microbiota during therapy [50]. If preventing resistance and
reducing CDI rates are targets for ASPs, then restricting oral vancomycin would seem sensible. However, we see
restrictions to the use of fidaxomicin, a drug shown to reduce rates of recurrent CDI when used frontline [51,52], to
potentially reduce 28 day all-cause mortality [53], and is not associated with colonization or spread of VRE [54]. The
often-cited ‘justification’ for this scenario is the high acquisition cost of fidaxomicin despite considerable evidence
demonstrating wider health economic benefits [55–58].
Innovation & stewardship
This all leads to a paradox. We want to prescribe the patient the right drug at the right time to provide the
best clinical outcome while minimizing unwanted downstream consequences; in other words, adhering to the
principles of stewardship. However, the absence of novel mechanism agents, and the fear of resistance emerging to
those few new agents we do have, often means stewardship considerations result in restricted access to appropriate
medicines. This was highlighted in Miller’s commentary on the approval of delafloxacin, describing a hypocritical
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stance of begging for, but then shunning use of, new antibiotics [59]. Whether perception or reality, if ASPs are
primarily about reducing drug acquisition costs, the situation is exacerbated by deterring investment resulting in
a dwindling pipeline. Pull incentives are a possible solution but challenges to their implementation, longevity and
assumption of continued significant formulary restriction continue to deter investment. Economic considerations,
while important, are not the principle purpose of ASPs and drug acquisition costs do not represent true wider
pharmacoeconomic benefit.
The situation is further compounded when evidence-based decisions to use an antibiotic are reliant on non-
inferiority (NI) trials. The NI test, which aims to establish that a new experimental treatment is not unacceptably
less efficacious than an active control treatment already in use [60,61], is currently required in settings beyond the
most serious and drug-resistant of infections as it is unethical to randomize patients to either placebo or an inferior
comparator. A new antibacterial may successfully meet the prespecified NI test and achieve regulatory approval but
the data pose challenges – the new drug appears to be ‘just as good’ or ‘no worse’ than the comparator which may
unfortunately limit its use [62,63]. This can be a somewhat superficial view. In certain settings, it may be impossible
to run anything other than a NI test on the primary end point, and so a more holistic view of the data by ASPs and
other groups is required to understand the true value of a new agent and its benefits for patients. This could include
data beyond initial cure such as wider pharmacoeconomic benefits, reduced readmissions and reduced infection
recurrence. However, in settings of particularly high unmet medical need superiority studies should be possible as
discussed by Powers et al. [64].
So how to resolve this conundrum and ensure that we, rightly, meet the overarching principles of stewardship?
Key is innovation – a shift away from the traditional approach of broad-spectrum agents, often from existing
classes and developed for multiple indications. Novel mechanism agents developed for specific infections to address
clear unmet needs aligns with stewardship goals. Such agents would have a spectrum of activity targeted toward
the pathogens of concern, be developed through clinical trials that show clear benefits over standard of care and
developed for use only in a specific infection or indication and not as ‘jack-of-all-trades’ agents. These would be
the appropriate therapies targeted to a specific patient need that stewardship requires, limiting the requirement for
excessive formulary restriction.
Multiple examples of where this precision approach could be adopted exist. For example, infections due to
Neisseria gonorrhoea are almost universally treated with ceftriaxone (often in combination with azithromycin), an
agent that should be used for severe infections, such as meningitis, cIAI and HAP [65]. Given global prevalence
of 106 million cases annually, and the ability of N. gonorrhoeae to develop, harbor and spread resistance, the
utility of ceftriaxone for indications where its use is more appropriate is threatened [66]. A novel class antibiotic for
gonorrhoea, developed and used only to treat gonorrhoea, would address a significant public health concern and
preserve ceftriaxone for use in severe infections.
Such an approach does come with significant scientific challenges. Identification of new classes of antibiotics
has proven difficult yet there is clear progress in this area. As of October 2017, 13 of the 17 projects funded
by CARB-X were novel mechanisms, chemotypes or approaches to treat bacterial infections [67], and more have
been funded subsequently. The Pew Trust identified 42 antibiotics in clinical development of which ten could
be considered novel [68], including murepavadin, a novel anti-Pseudomonas specific drug, now entering Phase
III trials [69]. In addition, numerous innovative and nontraditional technologies are emerging such as antisense,
engineered bacteriophages and microbiota-based therapies [70].
We can also now capitalize on regulatory innovation in trial designs. As part of the 21st Centuries Cures Act,
the Limited Population Antimicrobial Drug pathway emerged allowing for smaller, more feasible trials in limited
populations [71]. The recent positive opinion adopted by the Committee for Medicinal Products for Human Use
on meropenem/vaborbactam for the treatment of cUTI, cIAI and HAP/VAP on the basis of a large Phase III study
in cUTI [72], and a study in 77 subjects with confirmed or suspected CRE infection at a range of body sites [42],
further demonstrates the welcome and forward-thinking approach by regulators to help address the challenge of
antimicrobial resistance (AMR). Many other active and expert groups continue to propose innovative approaches
to clinical trials [73,74].
The use of such targeted antibiotics could be enabled on several fronts, led by increasingly sophisticated ASPs.
For example, the University Medical Centre in Groningen uses a model that integrates antimicrobial stewardship,
diagnostic stewardship and infection control into a patient centric, personalized care plan aimed at optimizing
clinical outcomes [75]. Pharmacists should have a more strategic role beyond contracting and containing the
cost of antimicrobials. Pharmacists with infectious diseases knowledge can impact on inappropriate antimicrobial
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regimens through various strategies, including optimizing prescribing behavior, monitoring antimicrobial use,
infection prevention and education, training and public engagement [76]. Stewardship not only requires use of
the appropriate drug, but also timely and appropriate dosing, sometimes aided by therapeutic drug monitoring
(TDM) which is increasingly recognized as important in treating infections in the critically ill [77–79]. To be effective,
TDM requires an individualized patient approach using a complex dataset; precision antibiotics for personalized
treatment could benefit from TDM, but factors such as access to drug assays and poor integration of PK software
with medical records, represent common barriers to effective implementation [80].
Major technological advances are potentially precipitating a revolution in rapid diagnostics providing pathogen
identification and susceptibility in hours not days. This has been extensively reviewed by others describing benefits
of their use in improving outcomes, including impacts on mortality [81–84]. Importantly, the benefits of rapid
diagnostics requires integration into ASPs to ensure correct use of tests, interpretation of results and again requires
close discussion between the microbiology lab, physician and wider ASP team to ensure timely action [82,84].
Intriguingly, an oft-cited barrier to implementation of new diagnostic technologies is cost – prescribing a broad-
spectrum generic antibiotic is simply cheaper than using a rapid diagnostic. This is another key example of the
challenges balancing immediate budget impact with wider cost and patient benefits.
Finally, if trial designs capture important outcomes data, such as reductions in unplanned interventions and
total care costs, it is then incumbent on payors and providers, including ASPs, to consider such data from both
individual patients and a population health perspective. We acknowledge, however, that more guidance is needed
to optimize such approaches.
Future perspective
Antimicrobial resistance (AMR) continues to advance and has reached unprecedented levels presenting a significant
challenge to modern medicine and patient welfare. However, a commercial model that does not offer a return on
the significant expenditure required to develop new, and especially truly innovative, antibiotics is stifling progress.
What could the future hold if we are to address the AMR crisis? A new way of developing antibacterials, focused
on novel mechanisms addressing specific unmet medical needs and developed to address specific indications; a
clear shift away from additional generations of established antibiotic classes that are often broad-spectrum agents
developed for multiple indications. A vibrant pipeline of such precision agents could alleviate resistance concerns
and provide clinicians with the targeted therapies they require to deliver the best outcomes for patients. Used
in more upfront settings, or at least not the very last resort, the commercial returns would improve, promoting
further R&D investment and limit the need for excessive restriction. However, this requires urgent action by all
parties involved in tackling infectious diseases, including drug developers, healthcare providers and policy makers.
Although efforts to address the commercial issues at the policy level have been slow, and the reality of large MERs
uncertain, we are highly encouraged to see the UK take a lead, though the NHS and NICE, with a pilot scheme
assessing a value-based model for antibiotic reimbursement [85]. However, the qualification criteria for an antibiotic
to be adopted as part of such a scheme, and the quantum of commercial return, remain unclear. In addition, the
UK alone cannot address these issues and a consistent global approach is required. Through all of this, stewardship
should remain a central component of our approach to infection management, but its core aim of optimizing
outcomes for patients should be re-emphasized.
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Executive summary
The problem of resistance coupled with an absence of innovation
• The widespread emergence of high-level antimicrobial resistance represents a major medical crisis.
• The pipeline of new antibiotics, especially innovative agents with new mechanisms of action addressing the most
worrisome of resistant pathogens, is sparse at best.
Aims, perceptions & realities of antimicrobial stewardship programs
• To address the issue of resistance, the concept of antimicrobial stewardship was developed to ensure the prudent
use of antibiotics to minimize resistance development and ensure the clinical longevity of the agents we have.
• The overarching aim of antimicrobial stewardship programs (ASPs) is a multidisciplinary approach to optimizing
clinical outcomes for patients through the use of the right antibiotic, in the right patient and at the right time.
• Despite many highly sophisticated ASPs being established that successfully result in improved clinical metrics such
as reduced resistance, reduced C. difficile infections and better patient outcomes, all too often ASPs are
measuring success on process metrics and minimizing drug acquisition costs.
• A broken commercial model for antibiotics and a pharmacy budget driven approach to stewardship, whether
perceived or actual, is stifling investment and innovation in novel antibiotic R&D resulting in the real threat of
the future returning to the pre-antibiotic era.
Personal perspective on one aspect of how to address the AMR crisis
• In this personal perspective, we propose that development of new mechanism, targeted and precision
antibacterials developed to address major unmet medical needs, is required to address the AMR crisis and that an
innovative approach to antimicrobial stewardship must play a fundamental role in helping to stimulate
innovation.
• It is incumbent on all those involved with infectious diseases, from drug developers to pharmacists, physicians
and administrators, to provide patients with life-threatening infections the medicines they need.
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